{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:25:30Z","timestamp":1764674730400,"version":"3.46.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ricerca Corrente Linea 1 and 2"},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>The management of SARS-CoV-2-infected patients with haematological malignancies and active disease is challenging, particularly in determining when to restart cancer therapy. This study evaluated the time to resumption of haematological therapy in adults with active haematological malignancies affected by SARS-CoV-2 infection and treated with either single-drug regimens (SR) or combined regimens (CR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>An observational cohort study was set up including patients with active haematological disease treated for SARS-CoV-2 infection between January 2022 and December 2023. Kaplan\u2013Meier estimates and Cox regression models were fitted to analyse the time to restarting anti-cancer therapy and factors associated with resumption within 60\u2005days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 79 patients included, 68 (86%) received SR, and 11 (14%) received CR. Patients on CR were more likely to require oxygen support (P = 0.006) and to have additional causes of immunosuppression (P = &amp;lt;0.001) compared with those on SR. The median time to restart therapy did not significantly differ between groups (38\u2005days [IQR 21\u201370] for SR versus 30\u2005days [IQR 18\u201377] for CR; P = 0.46). By Fine\u2013Gray competing risk regression analysis, pneumonia (HR 0.36, 95% CI 0.18\u20130.71), but not CR (HR 0.62, 95% CI 0.23\u20131.69), independently reduced the likelihood of restarting therapy within 60\u2005days of SARS-CoV-2 diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Combination regimens for SARS-CoV-2 did not affect the time to restart haematological therapy, whereas the occurrence of pneumonia was associated with delayed resumption of chemotherapy. The real benefit of COVID-19 combination therapy in the setting of haematologic malignancies, particularly for early treatment strategies, should be referred to the evidence from randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf342","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T11:37:00Z","timestamp":1758022620000},"page":"3236-3241","source":"Crossref","is-referenced-by-count":0,"title":["Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments"],"prefix":"10.1093","volume":"80","author":[{"given":"E","family":"Matteini","sequence":"first","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica\u2014Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Pinnetti","sequence":"additional","affiliation":[{"name":"Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Frondizi","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica\u2014Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-9584","authenticated-orcid":false,"given":"E","family":"Rando","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica\u2014Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario Virgen Macarena, Departamento de Medicina, Instituto de Biomedicina de Sevilla (IBiS)\/CSIC , Seville ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Chiuchiarelli","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica\u2014Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Metafuni","sequence":"additional","affiliation":[{"name":"Ematologia e Trapianto di Cellule Staminali Emopoietiche, Dipartimento di Scienze di Laboratorio ed Infettivologiche, Universit\u00e0 Cattolica del Sacro Cuore, Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Mastrorosa","sequence":"additional","affiliation":[{"name":"Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Alma","sequence":"additional","affiliation":[{"name":"Ematologia e Trapianto di Cellule Staminali Emopoietiche, Dipartimento di Scienze di Laboratorio ed Infettivologiche, Universit\u00e0 Cattolica del Sacro Cuore, Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-7504","authenticated-orcid":false,"given":"V","family":"Mazzotta","sequence":"additional","affiliation":[{"name":"Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Santangelo","sequence":"additional","affiliation":[{"name":"Department of Laboratory and Hematological Sciences Fondazione Policlinico Gemelli, IRCCS, Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics Catholic University School of Medicine, Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Department of Laboratory and Hematological Sciences Fondazione Policlinico Gemelli, IRCCS, Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9780-7059","authenticated-orcid":false,"given":"M","family":"Sanguinetti","sequence":"additional","affiliation":[{"name":"Department of Laboratory and Hematological Sciences Fondazione Policlinico Gemelli, IRCCS, Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics Catholic University School of Medicine, Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Sica","sequence":"additional","affiliation":[{"name":"Ematologia e Trapianto di Cellule Staminali Emopoietiche, Dipartimento di Scienze di Laboratorio ed Infettivologiche, Universit\u00e0 Cattolica del Sacro Cuore, Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Torti","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica\u2014Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-4684","authenticated-orcid":false,"given":"A","family":"Antinori","sequence":"additional","affiliation":[{"name":"Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Cingolani","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica\u2014Sezione di Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"author":"Pearce","key":"2025120206222991800_dkaf342-B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00233-3"},{"key":"2025120206222991800_dkaf342-B2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025120206222991800_dkaf342-B3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jinf.2021.01.022","article-title":"COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients","volume":"82","author":"Belsky","year":"2021","journal-title":"J Infect"},{"key":"2025120206222991800_dkaf342-B4","doi-asserted-by":"publisher","first-page":"2288480","DOI":"10.1080\/16078454.2023.2288480","article-title":"Impact of SARS-CoV-2 infection on patients with hematological malignancies: a retrospective study","volume":"28","author":"Zhao","year":"2023","journal-title":"Hematology"},{"key":"2025120206222991800_dkaf342-B5"},{"key":"2025120206222991800_dkaf342-B6","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41375-023-01938-5","article-title":"Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)","volume":"37","author":"Cesaro","year":"2023","journal-title":"Leukemia"},{"author":"Cathcart","key":"2025120206222991800_dkaf342-B7","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.09.434607"},{"key":"2025120206222991800_dkaf342-B8","doi-asserted-by":"publisher","first-page":"100794","DOI":"10.1016\/j.drup.2021.100794","article-title":"An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment","volume":"59","author":"Dro\u017cd\u017cal","year":"2021","journal-title":"Drug Resist Updat"},{"key":"2025120206222991800_dkaf342-B9","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"author":"Infectious Diseases Society of America","key":"2025120206222991800_dkaf342-B10"},{"key":"2025120206222991800_dkaf342-B11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12879-024-09466-y","article-title":"Early initiation of combined therapy in severely immunocompromised patients with COVID-19: a retrospective cohort study","volume":"24","author":"Rotundo","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2025120206222991800_dkaf342-B12","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1007\/s00277-024-05792-y","article-title":"Comprehensive procedure for injecting Evusheld\u00ae for hematological diseases in a single institute","volume":"103","author":"Imataki","year":"2024","journal-title":"Ann Hematol"},{"key":"2025120206222991800_dkaf342-B13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/hon.3206","article-title":"Dual combined antiviral treatment with remdesivir and nirmatrelvir\/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection","volume":"41","author":"Pasquini","year":"2023","journal-title":"Hematol Oncol"},{"key":"2025120206222991800_dkaf342-B14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ijid.2023.04.412","article-title":"Combination regimen of nirmatrelvir\/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: a case report and a scoping review of the literature","volume":"133","author":"Marangoni","year":"2023","journal-title":"Int J Infect Dis"},{"volume-title":"R: A Language and Environment for Statistical Computing","year":"2020","author":"R Core Team","key":"2025120206222991800_dkaf342-B15"},{"key":"2025120206222991800_dkaf342-B16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/cid\/ciac847","article-title":"Dual antiviral therapy for persistent coronavirus disease 2019 and associated organizing pneumonia in an immunocompromised host","volume":"76","author":"Trottier","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025120206222991800_dkaf342-B17","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/cid\/ciac868","article-title":"Successful treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a B cell acute lymphoblastic leukemia patient with an extended course of remdesivir and nirmatrelvir\/ritonavir","volume":"76","author":"Ford","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025120206222991800_dkaf342-B18","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/cid\/ciad085","article-title":"Successful combination treatment for persistent severe acute respiratory syndrome coronavirus 2 infection","volume":"76","author":"Blennow","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025120206222991800_dkaf342-B19","doi-asserted-by":"publisher","first-page":"ofac382","DOI":"10.1093\/ofid\/ofac382","article-title":"Extended remdesivir infusion for persistent coronavirus disease 2019 infection","volume":"9","author":"Martinez","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025120206222991800_dkaf342-B20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/jac\/dkac433","article-title":"Successful use of nirmatrelvir\/ritonavir in immunocompromised patients with persistent and\/or relapsing COVID-19","volume":"78","author":"Graziani","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025120206222991800_dkaf342-B21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jaci.2021.10.031","article-title":"Treatment of chronic or relapsing COVID-19 in immunodeficiency","volume":"149","author":"Brown","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025120206222991800_dkaf342-B22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijid.2021.04.068","article-title":"Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: a tailored approach","volume":"107","author":"D\u2019Abramo","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2025120206222991800_dkaf342-B23","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1186\/s12879-022-07774-9","article-title":"Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study","volume":"22","author":"Scaglione","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2025120206222991800_dkaf342-B24","doi-asserted-by":"publisher","first-page":"1062450","DOI":"10.3389\/fmed.2022.1062450","article-title":"Case report: sotrovimab, remdesivir and nirmatrelvir\/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19","volume":"9","author":"Baldi","year":"2023","journal-title":"Front Med"},{"key":"2025120206222991800_dkaf342-B25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40164-022-00307-9","article-title":"Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection","volume":"11","author":"Wada","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"2025120206222991800_dkaf342-B26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/joim.20030","article-title":"Incidence and predictors of clinical failure after early treatment for mild-to-moderate COVID-19 in high-risk individuals: a multicentric cohort study","volume":"297","author":"Mastrorosa","year":"2024","journal-title":"J Intern Med"},{"key":"2025120206222991800_dkaf342-B27","doi-asserted-by":"publisher","first-page":"107095","DOI":"10.1016\/j.ijantimicag.2024.107095","article-title":"Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: a prospective cohort study","volume":"63","author":"Calder\u00f3n-Parra","year":"2024","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3236\/64711148\/dkaf342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3236\/64711148\/dkaf342.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:22:38Z","timestamp":1764674558000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/12\/3236\/8286864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf342","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,15]]}}}